MEDIGENE IMMUNOTHERAPIES

What this means for you

Registered since 27 Dec 2022. The owner can stop confusingly similar uses in the classes it covers.

Record

Serial number

79309216

Registration number

6932587

Mark type

Stylized text

Filed

23 Feb 2021

Published for opposition

11 Oct 2022

Registered

27 Dec 2022

Attorney of record

Lisa C. Pavento

Goods and services

• Class 005 — Pharmaceuticals: Medicines for humans and animals, vaccines, serums for medical purposes, and diagnostic preparations for medical purposes for treating cancer, in particular manufactured using molecular biological, genetic engineering and biotechnological methods; test kits for principally comprised of diagnostic preparations for medical purposes that contains at least one of soluble t-cell receptors, and genetically modified cells for determining the type and existence of a tumour in a patient, in particular manufactured using molecular biological, genetic engineering and biotechnological methods; proteins and cells, namely, immune cells carrying a target specific effector protein, protein conjugates, peptides, enzymes and enzyme preparations, in particular antibodies and t-cell proteins, all for medical purposes; t-cells, dendritic cells other immune system cells, and viruses, all for medical purposes;plant extracts for medical purposes; medicines, vaccines, adjuvants, serums all for immunotherapy and the treatment of benign and malignant tumours, haematological tumours, inflammatory disorders, neurodegenerative disorders, and autoimmune conditions in particular manufactured using molecular biological, genetic engineering and biotechnological methods; test kits and diagnostic agents comprised of medical diagnostic preparations that contain at least one of soluble t-cell receptors and genetically modified cells for the diagnosis of benign and malignant tumours, haematological tumours, inflammatory disorders, neurodegenerative disorders, and autoimmune conditions in particular manufactured using molecular biological, genetic engineering and biotechnological methods
• Class 042 — Scientific and technological services: Custom molecular biology and biotechnology laboratory services, in particular custom research and development in the field of medical and veterinary diagnosis and treatment using molecular biological, genetic engineering and biotechnological methods to the specifications of others, and in the field of screening for pharmaceutically active components; development of custom test procedures and custom test kits in the field of biotechnology and medicine to the specification of others
• Class 044 — Medical, beauty and agricultural services: Medical analysis and medical consulting in connection with the treatment of individuals, in particular in the field of precancerous cells, benign and malignant tumours, autoimmune diseases and immunotherapy

Owner

• Medigene Immunotherapies GmbH, DE
• Medigene Immunotherapies GmbH, DE
• Medigene Immunotherapies GmbH, DE

Prosecution history

• 01 May 2023 — FINAL DECISION TRANSACTION PROCESSED BY IB
• 06 Apr 2023 — FINAL DISPOSITION NOTICE SENT TO IB
• 06 Apr 2023 — FINAL DISPOSITION PROCESSED
• 27 Mar 2023 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
• 27 Dec 2022 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
• 27 Dec 2022 — REGISTERED-PRINCIPAL REGISTER
• 17 Oct 2022 — NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
• 11 Oct 2022 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
• 11 Oct 2022 — PUBLISHED FOR OPPOSITION
• 10 Oct 2022 — NOTIFICATION PROCESSED BY IB
• 28 Sept 2022 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
• 28 Sept 2022 — NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
• 21 Sept 2022 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
• 21 Sept 2022 — NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
• 21 Sept 2022 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED